Literature DB >> 19680025

Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.

Aaref Badshah1, Mohammad Janjua, Fahad Younas, Abdul R Halabi, John F Cotant.   

Abstract

Torsade de pointes (TdP) or "twisting of the points" represents polymorphic ventricular tachycardia in the setting of prolonged QT interval and is characterized by QRS complexes that change in morphology and amplitude. We report a rare case of TdP, associated with QT interval prolongation, caused by intravenous moxifloxacin given for pneumonia in a 71-year-old African American man. Electrocardiogram initially revealed QT interval prolongation that led to torsades de pointes. These changes reverted to normal when moxifloxacin was held. Although the risk for quinolone-associated TdP seems to be low, caution is still warranted when given someone with high risk of QT prolongation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19680025     DOI: 10.1097/MAJ.0b013e3181a3c2c9

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

Review 1.  Thorough QT Studies: Questions and Quandaries.

Authors:  Marek Malik; Christine E Garnett; Joanne Zhang
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

2.  Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

Authors:  L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

3.  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.

Authors:  Nikunjkumar Patel; Oliver Hatley; Alexander Berg; Klaus Romero; Barbara Wisniowska; Debra Hanna; David Hermann; Sebastian Polak
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

4.  Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis.

Authors:  Einat Gorelik; Reem Masarwa; Amichai Perlman; Victoria Rotshild; Momen Abbasi; Mordechai Muszkat; Ilan Matok
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

5.  Update on the cardiac safety of moxifloxacin.

Authors:  Wilhelm Haverkamp; Frank Kruesmann; Anna Fritsch; David van Veenhuyzen; Pierre Arvis
Journal:  Curr Drug Saf       Date:  2012-04

6.  Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.

Authors:  Jose Vicente; Lars Johannesen; Meisam Hosseini; Jay W Mason; Philip T Sager; Esther Pueyo; David G Strauss
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

7.  The association between QT interval changes and the treatment protocols of COVID-19 patients.

Authors:  Yasar Sertbas; Kamil Ozdil; Sait Terzi; Selma Dagci; Bengu Saylan; Volkan Kizilay; Goktug Savas; Aysun Erdem Yaman; Meltem Sertbas; Habip Yilmaz; Cevdet Ugur Kocogullari
Journal:  North Clin Istanb       Date:  2022-07-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.